                         SEQUENCE LISTING

<110>  Allysta Pharmaceuticals, Inc.
       Hsu, Henry
       
 
<120>  Adiponectin Peptidomimetics for Treating Ocular Disorders

<130>  ALLY002.CIPPCT

<140>  Unassigned
<141>  2018-08-07

<150>  US 15/676,968
<151>  2017-08-14

<160>  7

<170>  PatentIn version 3.5

<210>  1
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa at position 1 may be Asn or a non-natural amino acid

<220>
<221>  MISC_FEATURE
<222>  (1)..(11)
<223>  provided that at least one of positions 1, 4, 7 or 10 is a 
       non-natural amino acid

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa at position 4 may be Gly or a non-natural amino acid

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa at position 7 may be Tyr or a non-natural amino acid

<220>
<221>  MISC_FEATURE
<222>  (10)..(11)
<223>  when Xaa at position 10 or Xaa at position 11 is a C-terminal 
       amino acid, said C-terminal amino acid is optionally amidated

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa at position 10 may be Tyr or a non-natural amino acid

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  Xaa at position 11 may be absent, bAla or bAlaNH2

<400>  1

Xaa Ile Pro Xaa Leu Tyr Xaa Phe Ala Xaa Xaa 
1               5                   10      


<210>  2
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa at position 1 is Asn or a non-natural amino acid

<220>
<221>  MISC_FEATURE
<222>  (1)..(10)
<223>  provided that at least one of Xaa at position 1, Xaa at position 
       4, Xaa at position 7 or Xaa at position 10 is a non-natural amino
       acid

<220>
<221>  MISC_FEATURE
<222>  (1)..(10)
<223>  wherein the C-terminal amino acid is optionally amidated

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa at position 4 is Gly or a non-natural amino acid

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa at position 7 is Tyr or a non-natural amino acid

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa at position 10 is Tyr or a non-natural amino acid

<400>  2

Xaa Ile Pro Xaa Leu Tyr Xaa Phe Ala Xaa 
1               5                   10  


<210>  3
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa at position 1 is D-Asn

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa at position 4 is Nva

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa at position 7 is D-Ser

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa at position 10 is D-Ser

<400>  3

Xaa Ile Pro Xaa Leu Tyr Xaa Phe Ala Xaa 
1               5                   10  


<210>  4
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa at position 1 is D-Asn

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa at position 4 is Nva

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa at position 7 is D-Ser

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa at position 10 is D-Ser

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  Xaa at position 11 is bAla

<400>  4

Xaa Ile Pro Xaa Leu Tyr Xaa Phe Ala Xaa Xaa 
1               5                   10      


<210>  5
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa at position 1 is D-Asn

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa at position 4 is Nva

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa at position 7 is D-Ser

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa at position 10 is D-Ser

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  Xaa at position 11 is bAlaNH2

<400>  5

Xaa Ile Pro Xaa Leu Tyr Xaa Phe Ala Xaa Xaa 
1               5                   10      


<210>  6
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa at position 1 is D-Asn

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa at position 4 is Nva

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa at position 7 is D-Ser

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa at position 10 is D-Ser-NH2

<400>  6

Xaa Ile Pro Xaa Leu Tyr Xaa Phe Ala Xaa 
1               5                   10  


<210>  7
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa at position 1 is D-Asn

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa at position 4 is Nva

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa at position 7 is D-Ser

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa at position 10 is D-Ser

<400>  7

Xaa Ile Pro Xaa Leu Tyr Xaa Phe Ala Xaa His Pro 
1               5                   10  

